EL CAJON, Calif.--(BUSINESS WIRE)--Nov. 1, 2024-- PURE Bioscience, Inc. (OTCQB: PURE) (“PURE,” the “Company” or “we”), creator of the patented non-toxic silver dihydrogen citrate (SDC) antimicrobial, and Quip Laboratories, Inc. (“Quip Labs”), have entered into a multi-year distribution agreement for the purchase and selling of SDC products under special terms and conditions.

PURE is pleased to announce the signing of a strategic distribution agreement with Quip Labs, a distinguished leader in solutions for the biomedical research, pharmaceutical production, companion animal care, and food processing industries. This partnership will enhance the accessibility of PURE's innovative products while ensuring superior safety and quality standards across these vital sectors.

“We are incredibly excited to partner with Quip Labs,” said Tim Steffensmeier, VP of Sales at PURE. “This agreement represents a significant step forward in our growth strategy, allowing us to leverage Quip Lab's expertise and established network. Together, we will provide even more comprehensive solutions that meet the biomedical, pharmaceutical, and food processing industries' unique needs while enhancing laboratory animal care.”

The partnership will enable both organizations to combine their resources and knowledge, ultimately delivering greater value to clients and ensuring that the highest quality and compliance standards are maintained throughout the industries in which Quip Labs services.

PURE will attend Quip Labs’ booth at the American Association for Laboratory Animal Science national meeting in Nashville, Tennessee, from November 3^rd to 7^th. It is also a sponsor of “Quip Labs Party for a Cause,” which will be held on November 6^th at the new Category 10 venue co-created by Luke Combs in Downtown Nashville.

“By joining forces with PURE, we are positioning ourselves to serve our customers better and respond to their needs quickly and efficiently,” added Nick Hidell, Chief Operating Officer at Quip Labs. “We look forward to collaborating with PURE to drive innovation and excellence across our industries.”

How SDC Works

SDC kills microorganisms by two modes of action: 1) the silver ion deactivates structural and metabolic membrane proteins, leading to microbial death; 2) the microbes view SDC as a food source, allowing the silver ion to enter the microbe. Once inside the organism, the silver ion denatures the DNA, which halts the microbe’s ability to replicate and leads to its death. This dual action makes SDC highly and quickly effective against a broad spectrum of microbes. Traditional silver-based disinfectants have short shelf lives – from hours to days. SDC is a stabilized silver ion complex with a shelf life of several years. The unique bond between the silver ions in SDC allows them to remain in solution while making them more bio-available for antimicrobial action.

About Quip Labs

Quip Laboratories is a leading provider of comprehensive facility hygiene solutions for a variety of industries, including the life sciences, healthcare, and food production markets. With a range of proprietary disinfectants and sterilants, as well as a best-in-class suite of decontamination and monitoring services, Quip Labs offers a comprehensive and eco-friendly approach to efficient facility hygiene. To reach out, please visit www.quiplabs.com or call 1.800.424.2436.

About PURE Bioscience, Inc.

PURE focuses on developing and commercializing our proprietary antimicrobial products, primarily in food safety. We provide solutions to combat the health and environmental challenges of pathogens and hygienic control. Our technology platform is based on patented, stabilized ionic silver, and our initial products contain silver dihydrogen citrate, better known as SDC. This broad-spectrum, non-toxic antimicrobial agent formulates well with other compounds. As a platform technology, SDC is distinguished from existing products in the marketplace because of its superior efficacy, reduced toxicity, and mitigation of bacterial resistance. PURE’s mailing address is 771 Jamacha Rd. #512, El Cajon, California 92019 (San Diego County area), serving as its official address for all business requirements. Additional information on PURE is available at www.purebio.com.

Forward-looking Statements: Any statements in this press release that do not describe historical facts may constitute forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Statements in this press release, including quotes from management, concerning the Company’s expectations, plans, business outlook, future performance, future potential revenues, and expected results of the Company’s marketing efforts, the execution of contracts under negotiation, and any other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are “forward-looking statements.” Forward-looking statements inherently involve risks and uncertainties that could cause our results to differ materially from any forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, the Company’s failure to implement or otherwise achieve the benefits of its proposed business initiatives and plans; acceptance of the Company’s current and future products and services in the marketplace, including the Company’s ability to convert successful evaluations and tests for PURE Control and PURE Hard Surface into customer orders and customers continuing to place product orders as expected and to expand their use of the Company’s products; the Company’s ability to maintain relationships with its partners and other counterparties; the Company’s ability to generate sufficient revenues and reduce its operating expenses in order to reach profitability; the Company’s ability to raise the funding required to support its continued operations and the implementation of its business plan; the ability of the Company to develop effective new products and receive required regulatory approvals for such products, including the required data and regulatory approvals required to use its SDC-based technology as a direct food contact processing aid in raw meat processing and to expand its use in OLR poultry processing; competitive factors, including customer acceptance of the Company’s SDC-based products that are typically more expensive than existing treatment chemicals; dependence upon third-party vendors, including to manufacture its products; and other risks detailed in the Company’s periodic report filings with the Securities and Exchange Commission (the SEC), including its Form 10-K for the fiscal year ended July 31, 2024. You should not rely on these forward-looking statements, which speak only as of the date of this press release. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241101647952/en/

Tim Steffensmeier, Vice President of Sales
PURE Bioscience, Inc.
Phone: 619-596-8600 Ext. 170

Source: PURE Bioscience, Inc.